Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sildenafil - Pfizer

Drug Profile

Sildenafil - Pfizer

Alternative Names: Revatio; Revatio IV; Sildenafil citrate; Sildenafil Citrate ODF - Pfizer; Sildenafil citrate orally-disintegrating film - Pfizer; UK 92480; Viagra

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Pfizer; University of Calgary
  • Class Antihypertensives; Erectile dysfunction therapies; Phenyl ethers; Piperazines; Purines; Pyrazoles; Pyrimidinones; Small molecules; Sulfonamides
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension; Heart failure; Pulmonary hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Erectile dysfunction; Pulmonary arterial hypertension
  • Phase III Diastolic heart failure; Heart failure; Pulmonary hypertension
  • No development reported Female infertility; Raynaud's disease
  • Discontinued Angina pectoris; Cardiovascular disorders; Eye disorders; Female sexual dysfunction; Meniere's disease

Most Recent Events

  • 06 Sep 2022 No development reported - Phase-III for Pulmonary hypertension (In neonates) in France (IV) (NDR Batch 23)
  • 14 Jun 2022 Pfizer completes the investigator-sponsored phase III SilHF trial in Heart failure (Treatment-experienced) in United Kingdom, Israel, Italy and Norway (NCT01616381)
  • 28 Sep 2020 Pfizer completes a phase III trials in Pulmonary Hypertension (In infants, In neonates) in Austria, Belgium, Canada, Denmark, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, Switzerland, UK and USA (IV) (NCT01720524)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top